EP. 1: Reflecting on Recent Updates, Changing Landscape of IgAN, with Jonathan Barratt, MD, PHD
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.
EP. 2: SPARTAN Trial Updates, with Jonathan Barratt, MD, PhD
In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN.
EP. 3: Long-term Options for IgAN Management, with Jonathan Barratt, MD, PhD
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.
EP. 4: Felzartamab Updates in IgAN from Kidney Week 2024, with Jonathan Barratt, MD, PhD
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.
EP. 5: How AFFINITY Informs on Potential of Atrasentan, with Jonathan Barratt, MD, PhD
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.
